https://doi.org/10.4081/hmr.v3i1.545

Innovative treatments: bortezomib

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 164
PDF: 148
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

PL Zinzani
support@pagepress.org
The incidence of non-Hodgkin's lymphoma (NHL) has markedly increased in the US and Western Europe in recent years and presents a considerable clinical challenge. Despite many advances in the treatment of NHL, the challenge to develop treatments far the disease remains. For example, there are few effective treatment options for patients with mantle celI lymphoma (MCL) and, while there are a number of therapies that can induce remission in patients with follicular lymphoma (FL), the disease remains incurable. Recently, preclinical and clinical studies have shown the potential for proteasome inhibition in the treatment of NHL.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Zinzani, P. (2009). Innovative treatments: bortezomib. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.545
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).